EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Phase I De-escalated RT in Endometrial Cancer

Joshua P Schiff, Silpa Raju-Salicki, Tyler R McKinnish, Omowumi Adekunle, Konstantina Stavroulaki, Casey Hatscher, Lulu Sun, Yi Huang, Julia Huecker, Daphne Lew, Premal H Thaker, Carolyn K McCourt und 11 weitere

International Journal of Radiation Oncology*Biology*Physics · 2026-07 · 125 (4) · 1101-1110

DOI: 10.1016/j.ijrobp.2026.01.015 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-07. Verfasst von Joshua P Schiff und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri; Department of Radiation Oncology, Keck School of Med…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Radiotherapy, Intensity-Modulated, Carcinosarcoma. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Washington University in St Louis School of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The safety and efficacy of hypofractionated radiation therapy (hypo-RT) and chemotherapy for locally advanced endometrial cancer is unknown. We evaluated the safety of hypo-RT sequenced after chemotherapy for patients with locally advanced endometrial cancer. METHODS AND MATERIALS: Patients with International Federation of Gynecology and Obstetrics 2009 stage III to IVA endometrioid adenocarcinoma, or any stage serous, clear cell, or carcinosarcoma of the uterus, were enrolled in this phase 1 trial (NCT#04386993). All patients underwent surgical staging and adjuvant chemotherapy followed by hypo-RT. Hypo-RT was intensity modulated RT 25 Gy/5 fractions delivered daily to the vaginal cuff and pelvis. The primary endpoint of this study was acute (first 90 days post-RT) and late (91 days to 12 months post-RT) high-grade (G3-5) gastrointestinal (GI), genitourinary (GU), and hematologic toxicities. Secondary endpoints included quality of life measures as well as in-field recurrence, locoregional control, distant control, disease-free survival, and overall survival. RESULTS: Twenty-five patients were enrolled, and all were evaluable for the primary endpoint. Notably, 60% had stage III disease and 60% had grade 3 disease. Most patients (21/25) completed 6 cycles of chemotherapy, and all patients (25/25) completed hypo-RT. The rate of acute treatment-related G3 GI, GU, and hematologic toxicity was 0% (0/25), 0% (0/25), and 12% (3/25). The rate of late treatment-related G3 GI, GU, and hematologic toxicity was 0% (0/25), 0% (0/25), and 4% (1/25). There were no G4-5 toxicities. At a median follow-up of 24.7 months from first chemotherapy treatment, there was 1 in-field recurrence (4%), 4 out-of-field paraortic recurrences (16%), 4 distant recurrences (16%), and 2 cancer-related deaths (8%). CONCLUSIONS: Hysterectomy followed by adjuvant chemotherapy and hypo-RT was safe. High-grade toxicities were low. This regimen may be worthy of evaluation in a randomized trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsRadiotherapy, Intensity-ModulatedCarcinosarcomaFemaleHumansAgedMiddle AgedQuality of LifeDisease-Free SurvivalRadiation Dose HypofractionationCarcinoma, EndometrioidChemotherapy, AdjuvantAdenocarcinoma, Clear CellNeoplasm Recurrence, LocalAdult

Autor:innen und Institutionen

  • Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri; Department of Radiation Oncology, Keck School of Medicine of University of Southern California, Los Angeles, California. E…
  • Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri.
  • Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.
  • Center for Biostatistics and Data Science, Washington University School of Medicine, St. Louis, Missouri.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri; Siteman Cancer Center, Washington University School of Medicine, St. Louis, Misso…

Förderung

  • Washington University in St Louis School of Medicine

Zitieren

APA

Schiff, J. P., Raju-Salicki, S., McKinnish, T. R., Adekunle, O., Stavroulaki, K., Hatscher, C., Sun, L., Huang, Y., Huecker, J., Lew, D., Thaker, P. H., McCourt, C. K., Massad, L. S., Kuroki, L. M., Hagemann, A. R., Powell, M. A., Khabele, D., Mutch, D., Badiyan, S. N., …, & Contreras, J. A. (2026). Phase I De-escalated RT in Endometrial Cancer. International Journal of Radiation Oncology*Biology*Physics, 125(4), 1101-1110. https://doi.org/10.1016/j.ijrobp.2026.01.015

Vancouver

Schiff JP, Raju-Salicki S, McKinnish TR, Adekunle O, Stavroulaki K, Hatscher C, et al. Phase I De-escalated RT in Endometrial Cancer. International Journal of Radiation Oncology*Biology*Physics. 2026;125(4):1101-1110. doi:10.1016/j.ijrobp.2026.01.015

BibTeX
@article{Schiff2026,
  author = {Schiff, Joshua P and Raju-Salicki, Silpa and McKinnish, Tyler R and Adekunle, Omowumi and Stavroulaki, Konstantina and Hatscher, Casey and Sun, Lulu and Huang, Yi and Huecker, Julia and Lew, Daphne and Thaker, Premal H and McCourt, Carolyn K and Massad, Leslie S and Kuroki, Lindsay M and Hagemann, Andrea R and Powell, Matthew A and Khabele, Dineo and Mutch, David and Badiyan, Shahed N and Lin, Alexander and Schwarz, Julie K and Markovina, Stephanie and Contreras, Jessika A},
  title = {Phase I De-escalated RT in Endometrial Cancer},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  volume = {125},
  number = {4},
  pages = {1101--1110},
  doi = {10.1016/j.ijrobp.2026.01.015}
}
Kostenlos starten →